Ascendis Pharma Growth Disorders A/S - CVR: 32323677

2023, EUR

03.04.2024

Bruttoresultat

-57.036'

Primær drift

-57.152'

Årets resultat

-61.381'

Aktiver

13.615'

Kortfristede aktiver

5.176'

Egenkapital

-202''

Afkastningsgrad

-420 %

Soliditetsgrad

-1482 %

Likviditetsgrad

+500%

Resultat

03.04.2024

Årsrapport	2023 03.04.2024	2022 24.03.2023	2021 09.05.2022	2020 29.03.2021	2019 11.05.2020	2018 22.05.2019	2017 18.05.2018	2016 11.05.2017
Nettoomsætning
Bruttoresultat	-57.035.666	-47.933.482	-30.184.950	-17.880.176	-14.434.891	-13.183.449	-5.944.352	-2.500.794
Resultat af primær drift	-57.152.128	-48.049.953	-30.301.148	-17.997.338	-14.543.541	-13.270.430	-6.030.920	0
Indtægter af kapitalandele (tilknyttede og associerede)	0	0	0	0	0	0	0	0
Finansielle indtægter	313	0	0	81	0	0	832	376
Finansieringsomkostninger	-4.305.042	-3.026.020	-1.858.498	-1.281.930	-796.123	-405.918	-131.565	-63.081
Andre finansielle omkostninger	0	0	0	0	0	0	0	0
Resultat før skat	-61.456.857	-51.075.973	-32.159.646	-19.279.187	-15.339.664	-13.676.348	-6.161.653	-2.648.714
Resultat	-61.381.172	-50.957.882	-32.098.569	-19.025.880	-15.339.664	-13.676.348	-6.149.421	-2.641.290
Forslag til udbytte	0	0	0	0	0	0	0	0

Aktiver

03.04.2024

Årsrapport	2023 03.04.2024	2022 24.03.2023	2021 09.05.2022	2020 29.03.2021	2019 11.05.2020	2018 22.05.2019	2017 18.05.2018	2016 11.05.2017
Kortfristede varebeholdninger	0	0	0	0	0	0	0	0
Kortfristede tilgodehavender fra salg og tjenesteydelser	5.168.840	1.096.404	2.241.641	2.128.950	2.544.241	799.175	852.143	40.338
Likvider	7.448	10.510	1.905.395	335	903.746	1.093.986	872.703	296.915
Kortfristede aktiver	5.176.288	1.106.914	4.147.036	2.129.285	3.447.987	1.893.161	1.724.846	337.253
Immaterielle aktiver og goodwill	0	0	54.545	109.091	163.637	218.182	318.881	165.777
Finansielle anlægsaktiver	8.439.087	8.439.087	6.529.096	6.529.096	6.529.096	0	0	0
Materielle aktiver	0	0	0	0	0	0	0	0
Langfristede aktiver	8.439.087	8.439.087	6.583.641	6.638.187	6.692.733	218.182	318.881	165.777
Aktiver	13.615.375	9.546.001	10.730.677	8.767.472	10.140.720	2.111.343	2.043.727	503.030

Aktiver

03.04.2024

Passiver

03.04.2024

Årsrapport	2023 03.04.2024	2022 24.03.2023	2021 09.05.2022	2020 29.03.2021	2019 11.05.2020	2018 22.05.2019	2017 18.05.2018	2016 11.05.2017
Forslag til udbytte	0	0	0	0	0	0	0	0
Egenkapital	-201.822.959	-140.441.787	-89.483.905	-57.385.336	-38.359.456	-23.019.792	-9.343.444	-3.194.023
Hensatte forpligtelser	0	0	0	0	0	0	0	0
Langfristet gæld til banker	0	0	0	0	0	0	0	0
Anden langfristet gæld	0	0	0	0	0	0	0	0
Leverandører af varer og tjenesteydelser	0	0	0	0	0	0	0	0
Kortfristede forpligtelser	5.917	5.876	3.005.688	942.086	3.198.132	564.235	524.986	161.268
Gældsforpligtelser	215.438.334	149.987.788	100.214.582	66.152.808	48.500.176	25.131.135	11.387.171	3.697.053
Forpligtelser	215.438.334	149.987.788	100.214.582	66.152.808	48.500.176	25.131.135	11.387.171	3.697.053
Passiver	13.615.375	9.546.001	10.730.677	8.767.472	10.140.720	2.111.343	2.043.727	503.030

Passiver

03.04.2024

Nøgletal

03.04.2024

Årsrapport	2023 03.04.2024	2022 24.03.2023	2021 09.05.2022	2020 29.03.2021	2019 11.05.2020	2018 22.05.2019	2017 18.05.2018	2016 11.05.2017
Afkastningsgrad	-419,8 %	-503,4 %	-282,4 %	-205,3 %	-143,4 %	-628,5 %	-295,1 %	Na.
Dækningsgrad	Na.	Na.	Na.	Na.	Na.	Na.	Na.	Na.
Resultatgrad	Na.	Na.	Na.	Na.	Na.	Na.	Na.	Na.
Varelagerets omsætningshastighed	Na.	Na.	Na.	Na.	Na.	Na.	Na.	Na.
Egenkapitals-forretning	30,4 %	36,3 %	35,9 %	33,2 %	40,0 %	59,4 %	65,8 %	82,7 %
Payout-ratio	Na.	Na.	Na.	Na.	Na.	Na.	Na.	Na.
Gældsdæknings-nøgletal	-1.327,6 %	-1.587,9 %	-1.630,4 %	-1.403,9 %	-1.826,8 %	-3.269,2 %	-4.584,0 %	Na.
Soliditestgrad	-1.482,3 %	-1.471,2 %	-833,9 %	-654,5 %	-378,3 %	-1.090,3 %	-457,2 %	-635,0 %
Likviditetsgrad	87.481,6 %	18.837,9 %	138,0 %	226,0 %	107,8 %	335,5 %	328,6 %	209,1 %

Resultat

03.04.2024

Gæld

03.04.2024

Årsrapport

03.04.2024

Nyeste:01.01.2023- 31.12.2023(offentliggjort: 03.04.2024)

Beretning

03.04.2024

Dato for ledelsens godkendelse af årsrapporten:2023-02-24

Oplysning om usædvanlige forhold:Impact from Covid-19 Pandemic The COVID-19 pandemic has affected countries where we are operating, where we have planned or have ongoing clinical trials, and where we rely on third-parties to manufacture preclinical, and clinical supply. While COVID-19 had an impact on how we work and conduct our activities, we have managed to avoid significant disruptions to our clinical and manufacturing operations. We monitor the risks from the pandemic closely, and work with relevant stakeholders to avoid and limit disruptions, and to develop and establish working measures. However, while COVID-19 continues to impact global societies, the uncertainty related to the duration and direction of the pandemic makes the future impact from COVID-19, including the magnitude of any impact on our operational results, highly uncertain and unpredictable.

Statement by Management on the annual report

Identifikation af den godkendte årsrapport:The Executive Board and Board of Directors have today considered and adopted the Annual Report of Ascendis Pharma Growth Disorders A/S for the financial year 1 January - 31 December 2022.